SCOPUS 정보 검색 플랫폼

New England Journal of Medicine

Volumn 369, Issue 11, 2013, Pages 1059-1060

Beyond exon 2 - The developing story of RAS mutations in colorectal cancer

(1) Berlin, Jordan a

a VANDERBILT INGRAM CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB;

COLORECTAL CANCER; DRUG EFFICACY; EDITORIAL; EXON; GENE EXPRESSION; GENE MUTATION; HUMAN; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

EID: 84883702548 PISSN: 00284793 EISSN: 15334406 Source Type: Journal
DOI: 10.1056/NEJMe1307992 Document Type: Editorial

Times cited : (15)

References (6)

1
- 34147103678
- Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
- DOI 10.1200/JCO.2006.08.1620
- Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64. (Pubitemid 46797944)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.13 , pp. 1658-1664
- Van Cutsem, E.¹ Peeters, M.² Siena, S.³ Humblet, Y.⁴ Hendlisz, A.⁵ Neyns, B.⁶ Canon, J.-L.⁷ Van Laethem, J.-L.⁸ Maurel, J.⁹ Richardson, G.¹⁰ Wolf, M.¹¹ Amado, R.G.¹²

2
- 36148941301
- Cetuximab for the treatment of colorectal cancer
- DOI 10.1056/NEJMoa071834
- Jonker DJ, O'Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8. (Pubitemid 350106711)
- (2007) New England Journal of Medicine , vol.357 , Issue.20 , pp. 2040-2048
- Jonker, D.J.¹ O'Callaghan, C.J.² Karapetis, C.S.³ Zalcberg, J.R.⁴ Tu, D.⁵ Au, H.-J.⁶ Berry, S.R.⁷ Krahn, M.⁸ Price, T.⁹ Simes, R.J.¹⁰ Tebbutt, N.C.¹¹ Van Hazel, G.¹² Wierzbicki, R.¹³ Langer, C.¹⁴ Moore, M.J.¹⁵

3
- 80052210041
- KRAS and colorectal cancer: Ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice
- Blanke CD, Goldberg RM, Grothey A, et al. KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist 2011;16:1061-8.
- (2011) Oncologist , vol.16 , pp. 1061-1068
- Blanke, C.D.¹ Goldberg, R.M.² Grothey, A.³

4
- 84883680951
- Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer
- Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
- (2013) N Engl J Med , vol.369 , pp. 1023-1034
- Douillard, J.-Y.¹ Oliner, K.S.² Siena, S.³

5
- 84883143101
- Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis
- September 3 (Epub ahead of print)
- To MD, Rosario RD, Westcott PMK, Banta KL, Balmain A. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 2012 September 3 (Epub ahead of print).
- (2012) Oncogene
- To, M.D.¹ Rosario, R.D.² Westcott, P.M.K.³ Banta, K.L.⁴ Balmain, A.⁵

6
- 79956298812
- Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
- Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status J Clin Oncol 2011;29:2011-9.
- (2011) J Clin Oncol , vol.29 , pp. 2011-2019
- Van Cutsem, E.¹ Kohne, C.H.² Lang, I.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.